Company Description
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus.
The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names.
It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin).
In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand.
It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.
| Country | Greece |
| Founded | 2009 |
| IPO Date | Dec 13, 2013 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Grigorios Siokas |
Contact Details
Address: 5 Agiou Georgiou Str, Pilea Thessaloniki, 55438 Greece | |
| Phone | 312 536 3102 |
| Website | cosmoshealthinc.com |
Stock Details
| Ticker Symbol | COSM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1474167 |
| CUSIP Number | 221413206 |
| ISIN Number | US2214133058 |
| Employer ID | 27-0611758 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Grigorios Siokas | Chairman and Chief Executive Officer |
| Georgios Terzis | Chief Financial Officer |
| Nikolaos Bardakis | Chief Operating Officer |
| Demetrios G. Demetriades | Secretary and Independent Director |
| Prof. Dimitrios Trafalis | Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 2, 2026 | DEF 14A | Other definitive proxy statements |
| May 22, 2026 | PRE 14A | Other preliminary proxy statements |
| May 22, 2026 | 8-K | Current Report |
| May 20, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 11, 2026 | RW | Filing |
| Apr 24, 2026 | SCHEDULE 13G/A | Filing |
| Apr 24, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 16, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 10-K | Annual Report |